Loading...
Please wait, while we are loading the content...
Similar Documents
Sarecycline: A Review of Preclinical and Clinical Evidence
| Content Provider | Scilit |
|---|---|
| Author | Moore, Angela Yen Rosso, James Del Johnson, Jodi L. Grada, Ayman |
| Copyright Year | 2020 |
| Description | Journal: Clinical, Cosmetic and Investigational Dermatology Sarecycline is a tetracycline-derived oral antibiotic, specifically designed for acne, and is approved by the Food and Drug Administration (FDA) in 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris (AV) in patients 9 years of age and older. It has been decades since a novel systemic antibiotic was approved to treat AV, a disease that affects up to 90% of teenagers and young adults worldwide and lasts well into adulthood. Sarecycline holds promise to yield fewer side effects than other commonly used broad-spectrum tetracyclines, including minocycline and doxycycline. The narrower spectrum of antibacterial activity of sarecycline, which specifically targets C. acnes and some Gram-positive bacteria with little or no activity against Gram-negative bacteria, suggests not only the potential for reduced emergence of antibiotic-resistant bacterial strains but also less disruption of the human gut microflora. Here, we review the key preclinical and clinical evidence on sarecycline. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431453/pdf https://www.dovepress.com/getfile.php?fileID=60620 |
| Ending Page | 560 |
| Page Count | 8 |
| Starting Page | 553 |
| ISSN | 11787015 |
| DOI | 10.2147/ccid.s190473 |
| Journal | Clinical, Cosmetic and Investigational Dermatology |
| Volume Number | ume 13 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2020-08-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Clinical, Cosmetic and Investigational Dermatology Acne Vulgaris Narrow Spectrum Tetracycline |
| Content Type | Text |
| Subject | Dermatology |